Market News & Trends
SunGen Pharma & Athenex Pharmaceutical Division Announce Injection Product Launch
SunGen Pharma recently announced the launch of Busulfan Injection, the second product launch through their joint venture Peterson Athenex with Athenex Pharmaceuticals. The ownership of…
CURE Pharmaceutical Expands US DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant
CURE Pharmaceutical recently announced it has broadened its US Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both…
Imugene Announces First Patient Dosed in Open-Label Phase 2 Study
Imugene Limited recently announced dosing of the first patient in an open-label, randomized multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the…
Santhera Completes Patient Enrollment in Phase IV Long-term Study
Santhera Pharmaceuticals recently announced it has completed patient enrollment in the ongoing Phase IV study (LEROS) with Raxone (idebenone) for the treatment of Leber's hereditary…
Cambrex Completes Expansion & Manufacturing Capability Upgrades
Cambrex Corporation recently announced it has completed the expansion of a new 150-m2 research and development laboratory at its site in Paullo, Milan, Italy. In…
Biogen Enters Agreement to Sell Its Large-Scale Biologics Manufacturing Site
Biogen recently announced it has entered into a share purchase agreement with FUJIFILM Corporation under which Fujifilm will acquire the shares of Biogen’s subsidiary, which…
Proper Fill & Finish in Clinical Development Requires a Comprehensive Approach
For pharma and biotech companies both large and small, the challenges involved in the fill and finish process of drugs for clinical development and scale-up continue to present new challenges.
Ajinomoto Bio-Pharma Services Announces Capital Expansion to Fuel Growth
Ajinomoto Bio-Pharma Services recently provided an update on several of its capital projects currently underway in both the United States and Belgium.
BioXcel Therapeutics Announces Addition of Merck KGaA & Pfizer to Clinical Collaboration With Nektar
BioXcel Therapeutics, Inc. recently announced the addition of Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada,…
Aptose Biosciences & CrystalGenomics Announce Issuance of Patent for Oral Small Molecule
Aptose Biosciences Inc. recently announced the Australian Patent Office (APO) has issued Australian Patent No. 2013371146 for CG-806, a first-in-class, highly potent oral small molecule…
ContraFect Announces $6.94 Million in Funding from CARB-X
ContraFect Corporation recently announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the company up to $6.94 million in non-dilutive funding to…
Lipomedix Announces Initiation of Phase 1b Trial
Lipomedix recently announced the initiation of a Phase 1b multicenter trial (LIPORAD-2018) to identify the optimal dose, safety, and efficacy of its lead compound Promitil…
Apellis Resumes Dosing in Its Phase 3 Program for Patients With Geographic Atrophy
Apellis Pharmaceuticals Inc. recently announced that with the agreement of the independent safety monitoring committee for the company’s Phase 3 clinical program for APL-2 in…
Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial
Ritter Pharmaceuticals, Inc. recently announced it has completed, ahead of schedule, enrollment in its first pivotal Phase 3 clinical trial of RP-G28 for the potential…
Procarta Announces Significant Investment for New Class of Antibiotics
Procarta Biosystems recently announced $1.7 million of new funding from the Novo Holdings REPAIR Impact Fund to support development of novel therapies to combat antimicrobial resistance (AMR).
Biogen Announces Agreement to Acquire Nightstar Therapeutics
Biogen recently announced it has entered into an agreement to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Catalent Invests Over $27 Million to Commercialize ODT Technology
Catalent Pharma Solutions recently announced that it is to invest more than $27 million to commercialize its next-generation oral disintegrating tablet (ODT) technology, Zydis Ultra.
Nemera’s Preservative-Free Multidose Eye Dropper Approved for Santen’s Drug in 29 European Countries
Nemera recently announce its multidose eye dropper Novelia has been approved for the preservative-free formulation Cosopt iMulti (20 mg/ml dorzolamide + 5 mg/ml timolol eye drops, solution).
SGS Appoints Biologics Manager at Expanded Life Sciences Facility in Illinois
SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, today announced the appointment of Dr. Haris Jamil as Biologics Manager of its recently expanded biopharmaceutical testing facility in Lincolnshire, Illinois, USA.
Sarepta Therapeutics Announces Positive & Robust Expression & Biomarker Data
Sarepta Therapeutics, Inc. recently announced positive results from three Limb-girdle muscular dystrophy (LGMD) Type 2E clinical trial participants who received MYO-101. MYO-101 is a novel…
